RU2010116781A - Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение - Google Patents
Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение Download PDFInfo
- Publication number
- RU2010116781A RU2010116781A RU2010116781/15A RU2010116781A RU2010116781A RU 2010116781 A RU2010116781 A RU 2010116781A RU 2010116781/15 A RU2010116781/15 A RU 2010116781/15A RU 2010116781 A RU2010116781 A RU 2010116781A RU 2010116781 A RU2010116781 A RU 2010116781A
- Authority
- RU
- Russia
- Prior art keywords
- transcription factor
- disorders
- ligand
- diseases
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
Abstract
1. Способ лечения, облегчения или профилактики заболевания, нарушения или патологического состояния у субъекта, включающий: ! (a) введение в организм указанного субъекта (1) первого полинуклеотида, кодирующего переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции (LDTFC) посредством функциональной ассоциации с терапевтическим промотором переключателя, и (2) второй полинуклеотид, кодирующий терапевтический полипептид или терапевтический полинуклеотид, функционально связанный с фактор-регулируемым промотором, который активируется указанным комплексом лиганд-зависимого фактора транскрипции, причем указанные первый и второй полинуклеотиды вводят таким образом, чтобы обеспечить экспрессию указанного комплекса лиганд-зависимого фактора транскрипции; и ! (b) введение лиганда указанному субъекту для индуцирования экспрессии указанного терапевтического полипептида или терапевтического полинуклеотида. ! 2. Способ экспрессии терапевтического полипептида или терапевтического полинуклеотида в организме субъекта, включающий: ! (a) введение в организм субъекта (1) первого полинуклеотида, кодирующего переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции (LDTFC) посредством функциональной ассоциации с те
Claims (24)
1. Способ лечения, облегчения или профилактики заболевания, нарушения или патологического состояния у субъекта, включающий:
(a) введение в организм указанного субъекта (1) первого полинуклеотида, кодирующего переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции (LDTFC) посредством функциональной ассоциации с терапевтическим промотором переключателя, и (2) второй полинуклеотид, кодирующий терапевтический полипептид или терапевтический полинуклеотид, функционально связанный с фактор-регулируемым промотором, который активируется указанным комплексом лиганд-зависимого фактора транскрипции, причем указанные первый и второй полинуклеотиды вводят таким образом, чтобы обеспечить экспрессию указанного комплекса лиганд-зависимого фактора транскрипции; и
(b) введение лиганда указанному субъекту для индуцирования экспрессии указанного терапевтического полипептида или терапевтического полинуклеотида.
2. Способ экспрессии терапевтического полипептида или терапевтического полинуклеотида в организме субъекта, включающий:
(a) введение в организм субъекта (1) первого полинуклеотида, кодирующего переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции (LDTFC) посредством функциональной ассоциации с терапевтическим промотором переключателя, и (2) второй полинуклеотид, кодирующий указанный терапевтический полипептид или терапевтический полинуклеотид, функционально связанный с фактор-регулируемым промотором, который активируется указанным комплексом лиганд-зависимого фактора транскрипции, причем указанные первый и второй полинуклеотиды вводят таким образом, чтобы обеспечить экспрессию указанного комплекса лиганд-зависимого фактора транскрипции; и
(b) введение лиганда указанному субъекту для индуцирования экспрессии указанного терапевтического полипептида или терапевтического полинуклеотида.
3. Способ по п.1 или 2, отличающийся тем, что указанное заболевание, нарушение или патологическое состояние восприимчиво к указанному терапевтическому полипептиду или терапевтическому полинуклеотиду.
4. Способ по п.1 или 2, отличающийся тем, что указанный переключатель гена представляет собой переключатель гена на основе рецептора экдизона (EcR).
5. Способ по п.1 или 2, отличающийся тем, что указанный лиганд представляет собой диацилгидразин.
6. Способ по п.1 или 2, отличающийся тем, что указанный лиганд представляет собой амидокетон или оксадиазолин.
7. Способ по п.1 или 2, отличающийся тем, что указанный переключатель гена содержит первую последовательность фактора транскрипции под контролем первого терапевтического промотора переключателя и вторую последовательность фактора транскрипции под контролем второго терапевтического промотора переключателя, причем белки, кодируемые указанной первой последовательностью фактора транскрипции и указанной второй последовательностью фактора транскрипции взаимодействуют с образованием белкового комплекса, который функционирует как комплекс лиганд-зависимого фактора транскрипции.
8. Способ по п.1 или 2, отличающийся тем, указанные модифицированные клетки являются модифицированными неаутологичными клетками (MNA), в которые ввели указанные первый и второй полинуклеотиды.
9. Способ по п.1 или 2, отличающийся тем, что указанные модифицированные клетки обработаны таким образом, чтобы при введении субъекту защитить указанные клетки от иммунной системы указанного субъекта.
10. Способ экспрессии терапевтического полипептида или терапевтического полинуклеотида в одной или более модифицированных клетках, включающий:
(a) введение в клетку (1) первого полинуклеотида, кодирующего переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции посредством функциональной ассоциации с терапевтическим промотором переключенателя, и (2) второй полинуклеотид, кодирующий терапевтический полипептид или терапевтический полинуклеотид, функционально связанный с фактор-регулируемым промотором, который активируется указанным комплексом лиганд-зависимого фактора транскрипции с получением модифицированной клетки;и
(b) введение лиганда в указанную модифицированную клетку для индуцирования экспрессии указанного терапевтического полипептида или терапевтического полинуклеотида.
11. Композиция нуклеиновой кислоты, содержащая первый полинуклеотид, кодирующий переключатель гена, где указанный переключатель гена содержит по меньшей мере одну последовательность фактора транскрипции, причем указанная по меньшей мере одна последовательность фактора транскрипции кодирует комплекс лиганд-зависимого фактора транскрипции посредством функциональной ассоциации с терапевтическим промотором переключателя.
12. Композиция нуклеиновой кислоты по п.11, которая дополнительно содержит второй полинуклеотид, кодирующий полипептид или полинуклеотид, ассоциированный с заболеванием, нарушением или патологическим состоянием, функциональным образом ассоциированный с промотором, который активируется указанным комплексом лиганд-зависимого фактора транскрипции.
13. Композиция нуклеиновой кислоты по п.11, отличающаяся тем, что указанный переключатель гена представляет собой переключатель гена на основе EcR.
14. Композиция нуклеиновой кислоты по п.13, отличающаяся тем, что указанный лиганд связывается с лиганд-связывающим доменом EcR.
15. Композиция нуклеиновой кислоты по п.14, отличающаяся тем, что указанный лиганд представляет собой диацилгидразин.
16. Вектор, который содержит композицию нуклеиновой кислоты по п.12.
17. Вектор по п.16, который представляет собой вирусный вектор.
18. Набор, содержащий композицию нуклеиновой кислоты по п.12.
19. Способ получения модифицированной клетки, включающий введение в клетку вектора по п.16.
20. Модифицированная клетка, содержащая композицию нуклеиновой кислоты по любому из пп.11-15.
21. Устройство биореактора, содержащее одну или более модифицированных клеток согласно п.20.
22. Применение композиции нуклеиновой кислоты по любому из пп.11-15 при приготовлении лекарственного препарата для лечения заболевания, нарушения или патологического состояния, выбранного из группы, включающей гиперпролиферативные заболевания, нарушения или патологические состояния, сердечно-сосудистые заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния нервной системы, аутоиммунные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния костей, желудочно-кишечные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния крови, метаболические заболевания, нарушения или патологические состояния, воспалительные заболевания, нарушения или патологические состояния и инфекционные заболевания, нарушения или патологические состояния.
23. Применение вектора по любому из пп.16-17 при приготовлении лекарственного препарата для лечения заболевания, нарушения или патологического состояния, выбранного из группы, включающей гиперпролиферативные заболевания, нарушения или патологические состояния, сердечно-сосудистые заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния нервной системы, аутоиммунные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния костей, желудочно-кишечные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния крови, метаболические заболевания, нарушения или патологические состояния, воспалительные заболевания, нарушения или патологические состояния и инфекционные заболевания, нарушения или патологические состояния.
24. Применение модифицированной клетки по п.20 при приготовлении лекарственного препарата для лечения заболевания, нарушения или патологического состояния, выбранного из группы, включающей гиперпролиферативные заболевания, нарушения или патологические состояния, сердечно-сосудистые заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния нервной системы, аутоиммунные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния костей, желудочно-кишечные заболевания, нарушения или патологические состояния, заболевания, нарушения или патологические состояния крови, метаболические заболевания, нарушения или патологические состояния, воспалительные заболевания, нарушения или патологические состояния и инфекционные заболевания, нарушения или патологические состояния.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97598607P | 2007-09-28 | 2007-09-28 | |
| US60/975,986 | 2007-09-28 | ||
| US4789908P | 2008-04-25 | 2008-04-25 | |
| US61/047,899 | 2008-04-25 | ||
| PCT/US2008/011270 WO2009045370A2 (en) | 2007-09-28 | 2008-09-29 | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010116781A true RU2010116781A (ru) | 2011-11-10 |
| RU2499599C2 RU2499599C2 (ru) | 2013-11-27 |
Family
ID=40526874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010116781/15A RU2499599C2 (ru) | 2007-09-28 | 2008-09-29 | Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20090136465A1 (ru) |
| EP (1) | EP2205249B1 (ru) |
| JP (2) | JP2010540534A (ru) |
| KR (1) | KR101666228B1 (ru) |
| CN (1) | CN101868241A (ru) |
| AU (1) | AU2008307643B9 (ru) |
| BR (1) | BRPI0817233A2 (ru) |
| CA (1) | CA2715080C (ru) |
| IL (1) | IL204731B (ru) |
| MX (1) | MX2010003371A (ru) |
| NZ (1) | NZ584848A (ru) |
| RU (1) | RU2499599C2 (ru) |
| WO (1) | WO2009045370A2 (ru) |
| ZA (1) | ZA201002848B (ru) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008289461A1 (en) * | 2007-08-23 | 2009-02-26 | Intrexon Corporation | Methods and compositions for diagnosing disease |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| ES2531522T3 (es) * | 2007-10-08 | 2015-03-16 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
| WO2010042189A2 (en) | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
| CA2755192C (en) | 2009-03-20 | 2018-09-11 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
| WO2010138180A2 (en) | 2009-05-26 | 2010-12-02 | The University Of Vermont And State Agriculture College | Compositions and methods for cardiac tissue repair |
| CA2769262C (en) | 2009-07-28 | 2019-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
| ES2613302T3 (es) | 2010-12-02 | 2017-05-23 | Neurotech Usa, Inc. | Líneas celulares que segregan estructuras de anticuerpos anti-angiogénicas y receptores solubles y usos de los mismos |
| SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| CN106187812A (zh) * | 2011-09-08 | 2016-12-07 | 英特瑞克斯顿股份有限公司 | 结晶状二酰基肼及其用途 |
| WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| EP3808844A1 (en) * | 2012-07-25 | 2021-04-21 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| CA2886684C (en) | 2012-10-10 | 2023-09-19 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| CN105934524A (zh) | 2013-11-11 | 2016-09-07 | 桑格摩生物科学股份有限公司 | 用于治疗亨廷顿氏病的方法和组合物 |
| FR3014316B1 (fr) * | 2013-12-10 | 2017-01-20 | Defymed | Organe bioartificiel |
| CA2942762C (en) | 2014-03-18 | 2023-10-17 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| CA2964927C (en) | 2014-10-20 | 2019-07-30 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
| JP7017932B2 (ja) * | 2014-12-09 | 2022-02-09 | ニューヨーク・ユニバーシティ | クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法 |
| WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| MA43404A (fr) * | 2015-11-11 | 2018-10-17 | Intrexon Corp | Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques |
| AU2016369490C1 (en) | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| IL297018A (en) | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| EP3235516B1 (en) | 2016-04-22 | 2019-06-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | Regulatable adeno-associated virus (aav) vector |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| SG10201913948PA (en) | 2016-08-24 | 2020-03-30 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| AU2018256877B2 (en) | 2017-04-28 | 2022-06-02 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA3059793A1 (en) | 2017-05-03 | 2018-11-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
| IL306102A (en) | 2017-06-07 | 2023-11-01 | Precigen Inc | Expression of new cell markers |
| US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| KR20200128703A (ko) | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | B형 간염 백신 및 이의 용도 |
| JP7332622B2 (ja) | 2018-04-18 | 2023-08-23 | サンガモ セラピューティクス， インコーポレイテッド | ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物 |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| KR20210052443A (ko) * | 2018-07-17 | 2021-05-10 | 뉴로마이언 주식회사 | Igf-1 이형체를 발현하는 dna 컨스트럭트를 이용한 신경병증의 치료 |
| CN113015741A (zh) | 2018-09-18 | 2021-06-22 | 桑格摩生物治疗股份有限公司 | 程序性细胞死亡1(pd1)特异性核酸酶 |
| CN110946988B (zh) * | 2018-09-26 | 2022-11-29 | 臻崴生物科技有限公司 | 短肽用于制备抑制或减缓虾过敏反应的药物组合物的用途 |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| CN113474328A (zh) | 2019-01-11 | 2021-10-01 | 爱康泰生治疗公司 | 用于脂质纳米颗粒递送活性剂的脂质 |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| MX2019015589A (es) * | 2019-12-19 | 2021-06-21 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
| CN115397474A (zh) * | 2020-02-11 | 2022-11-25 | 威廉马歇莱思大学 | 用于改善治疗剂递送的方法 |
| CN111704705B (zh) * | 2020-06-24 | 2021-06-08 | 河南大学 | 一种嵌段聚合物及其制备方法以及一种载药囊泡和靶向载药囊泡 |
| EP4182297A1 (en) | 2020-07-16 | 2023-05-24 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
| WO2024081310A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (451)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4409331A (en) | 1979-03-28 | 1983-10-11 | Damon Corporation | Preparation of substances with encapsulated cells |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| CA1196862A (en) | 1983-06-01 | 1985-11-19 | Anthony M.F. Sun | Microencapsulation of living tissue and cells |
| US4689293A (en) | 1983-06-06 | 1987-08-25 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| US4806355A (en) * | 1983-06-06 | 1989-02-21 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| US4680174A (en) | 1984-05-24 | 1987-07-14 | Damon Biotech, Inc. | Induction of immune response by immunization with encapsulated antigen-producing cells |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5082779A (en) * | 1987-08-06 | 1992-01-21 | Edison Animal Biotechnology Center/Ohio University | Method of directing transgenic expression in animals using a prolactin promoter |
| US5786216A (en) | 1987-11-17 | 1998-07-28 | Cytotherapeutics, Inc. | Inner-supported, biocompatible cell capsules |
| US5773286A (en) | 1987-11-17 | 1998-06-30 | Cytotherapeutics, Inc. | Inner supported biocompatible cell capsules |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5266488A (en) | 1988-04-06 | 1993-11-30 | The Regents Of The University Of California | Troponin T gene promoter and derivatives thereof |
| US5340739A (en) | 1988-07-13 | 1994-08-23 | Brigham & Women's Hospital | Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof |
| US5853985A (en) | 1988-08-30 | 1998-12-29 | Bayer Aktiegsesellschaft | Promoter of the gene for the human precursor of the alzheimer's disease and its use |
| US5151508A (en) | 1988-08-30 | 1992-09-29 | Molecular Therapetuics, Inc. | Promoter region for DNA sequences which encode the precursor of the human A4 amyloid protein |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5773215A (en) | 1989-10-24 | 1998-06-30 | Board Of Regents, The University Of Texas System | Tumor marker protein for cancer risk assessment |
| AU7174791A (en) | 1990-01-26 | 1991-08-21 | Baylor College Of Medicine | Mutated promoter region from chicken skeletal alpha-actin gene |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
| US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| US5288846A (en) * | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
| US5831141A (en) | 1991-01-11 | 1998-11-03 | United States Of America As Represented By The Department Of Health And Human Services | Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter |
| IL100643A (en) * | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US5800829A (en) | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| JP4215273B2 (ja) | 1991-04-25 | 2009-01-28 | ブラウン ユニヴァーシティ リサーチ ファンデーション | 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル |
| US5352595A (en) | 1991-09-03 | 1994-10-04 | Fred Hutchinson Cancer Research Center | Myod regulatory region |
| AU3124793A (en) | 1991-10-29 | 1993-06-07 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
| US5545423A (en) | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
| JP3430296B2 (ja) | 1992-01-23 | 2003-07-28 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | ヒト表皮遺伝子プロモーター |
| US5753502A (en) | 1993-08-05 | 1998-05-19 | Icos Corporation | Neuron-specific ICAM-4 promoter |
| US5556954A (en) | 1992-02-13 | 1996-09-17 | Beth Israel Hospital Boston Association | Hematopoietic stem cell specific gene expression |
| US6013836A (en) * | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5334640A (en) | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
| US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1994012519A1 (en) * | 1992-11-25 | 1994-06-09 | Brigham And Women's Hospital | Epstein barr virus induced genes |
| US5811231A (en) * | 1993-01-21 | 1998-09-22 | Pres. And Fellows Of Harvard College | Methods and kits for eukaryotic gene profiling |
| US5627023A (en) | 1993-03-29 | 1997-05-06 | Duke University | Suppressor of HIV replication and transcription |
| EP0746582B1 (en) * | 1993-04-27 | 2000-03-15 | Cytotherapeutics, Inc. | Membrane formed by an acrylonitrile-based polymer |
| US5698413A (en) * | 1993-05-05 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of evaluating chemotherapeutic agents in vivo |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| CN1129402A (zh) | 1993-06-23 | 1996-08-21 | 布朗大学研究基金会 | 密封可植入的薄膜封装件的方法和装置 |
| US5908623A (en) | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| EP0802800B1 (en) | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| WO1995013375A1 (en) | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| ES2260568T3 (es) * | 1994-01-13 | 2006-11-01 | The Rogosin Institute | Celulas secretoras macroencapsuladas. |
| USRE39542E1 (en) | 1994-01-13 | 2007-04-03 | The Rogosin Institute | Preparation of agarose coated, solid agarose-collagen beads containing secretory cells |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US5661032A (en) | 1994-03-18 | 1997-08-26 | Mcgill University | Tα1 α-tubulin promoter and expression vectors |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5651980A (en) | 1994-04-15 | 1997-07-29 | Biohybrid Technologies, Inc. | Methods of use of uncoated gel particles |
| US5518885A (en) | 1994-04-19 | 1996-05-21 | The United States Of America As Represented By The Department Of Health & Human Services | ERBB2 promoter binding protein in neoplastic disease |
| US5959094A (en) | 1994-05-11 | 1999-09-28 | Yeda Research And Development Co. Ltd. | p75 TNF receptor promoters |
| US6150137A (en) * | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| US5668012A (en) | 1994-07-05 | 1997-09-16 | The Blood Center Research Foundation, Inc. | Platelet endothelial cell adhesion molecule-1 promoters and uses thereof |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| JPH10506011A (ja) * | 1994-09-22 | 1998-06-16 | ヘルシンキ、ユニバーシティ、ライセンシング、リミテッド、オサケ、ユキチュア | レセプターチロシンキナーゼ、ｔｉｅのプロモーター |
| US6306454B1 (en) | 1994-10-17 | 2001-10-23 | Baxter International Inc. | Method for producing improved medical devices and devices so produced |
| US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
| US5643726A (en) | 1994-11-10 | 1997-07-01 | The General Hospital Corporation | Methods for modulating transcription from the amyloid β-protein precursor (APP) promoter |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| US6177242B1 (en) * | 1994-12-14 | 2001-01-23 | Institut Pasteur | Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments |
| US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US5824794A (en) | 1994-12-23 | 1998-10-20 | Syntex (U.S.A.) Inc. | Human stromelysin-1 promoter |
| US5834306A (en) * | 1994-12-23 | 1998-11-10 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
| US5888764A (en) * | 1995-01-20 | 1999-03-30 | Uab Research Foundation | Human fas gene promoter region |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| ATE317435T1 (de) | 1995-02-24 | 2006-02-15 | Sloan Kettering Inst Cancer | Prostataspezifisches membranes antigen und seine anwendungen |
| WO1996027673A1 (en) | 1995-03-03 | 1996-09-12 | Novartis Ag | Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand |
| US5916790A (en) | 1995-03-03 | 1999-06-29 | Metabolex, Inc. | Encapsulation compositions, and methods |
| US6126936A (en) | 1995-03-10 | 2000-10-03 | Biohybrid Technologies Llc | Microcapsules and composite microreactors for immunoisolation of cells |
| US5866323A (en) * | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| WO1996034101A1 (en) | 1995-04-24 | 1996-10-31 | Medical Research Council | Utrophin gene promoter |
| JPH11506319A (ja) | 1995-05-26 | 1999-06-08 | ゼネカ・リミテッド | エクジソンレセプターを含む遺伝子スイッチ |
| US5744304A (en) * | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| US7033746B2 (en) | 1995-06-06 | 2006-04-25 | New England Medical Center Hospitals, Inc. | NES-1 polypeptides, DNA, and related molecules and methods |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5888765A (en) * | 1995-06-23 | 1999-03-30 | President And Fellows Of Harvard College | Endothelial-cell specific promoter |
| US6306649B1 (en) | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
| GB2302874B (en) | 1995-06-29 | 1999-11-10 | Orion Yhtymae Oy | Novel proteins |
| WO1997010807A1 (en) | 1995-09-22 | 1997-03-27 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| GB9519490D0 (en) | 1995-09-25 | 1995-11-29 | Melvin William T | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
| US5866329A (en) * | 1995-09-27 | 1999-02-02 | Demetriou; Achilles A. | Method and probe for detection of gene associated with liver neoplastic disease |
| AU1059897A (en) | 1995-11-09 | 1997-05-29 | Trustees Of Boston University | Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector |
| US5837534A (en) | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| US5698389A (en) | 1995-11-16 | 1997-12-16 | Tularik, Inc. | Transcriptional promoter of the murine obesity gene |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| CA2191903A1 (en) | 1995-12-20 | 1997-06-21 | Jun Ikeda | Stress proteins |
| US6323329B1 (en) | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
| CN101712720A (zh) | 1996-02-09 | 2010-05-26 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
| US5681706A (en) | 1996-03-01 | 1997-10-28 | Health Research Inc. | Mammalian anoxia-responsive regulatory element |
| CN1187452C (zh) | 1996-03-12 | 2005-02-02 | 株式会社载体研究所 | 启动子 |
| US6468766B1 (en) | 1996-03-15 | 2002-10-22 | President And Fellows Of Harvard College | Aortic carboxypeptidase-like polypeptide |
| US5952223A (en) | 1996-03-22 | 1999-09-14 | Millennium Pharmaceuticals | Compositions for the diagnosis and treatment of Chediak-Higashi syndrome |
| US5763591A (en) | 1996-03-25 | 1998-06-09 | Cedars-Sinai Medical Center | Polynucleic acid sequences that are functionally associated with the development of autoimmune disease |
| US6224912B1 (en) | 1996-04-03 | 2001-05-01 | The Rogo Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| CA2251466A1 (en) * | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6696557B1 (en) | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| WO1998000563A1 (fr) | 1996-06-28 | 1998-01-08 | Chugai Seiyaku Kabushiki Kaisha | Procede de detection d'une activite telomerase |
| US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
| US5744310A (en) * | 1996-07-29 | 1998-04-28 | The Burnham Institute | Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression |
| US20010011128A1 (en) | 1996-09-25 | 2001-08-02 | Gerald Batist | Hex II tumor-specific promoter and uses thereof |
| US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
| US20040086494A1 (en) * | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
| US5773290A (en) | 1996-10-07 | 1998-06-30 | Wisconsin Alumni Research Foundation | Mammary gland-specific promoters |
| US6673911B1 (en) * | 1996-11-19 | 2004-01-06 | Chiron Corporation | Human polyhomeotic 2 (hph2) acts as an oncogene |
| US5772993A (en) | 1997-01-21 | 1998-06-30 | The University Of Virginia Patent Foundation | Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues |
| US6794131B1 (en) | 1998-01-27 | 2004-09-21 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
| US7138511B1 (en) | 1997-01-28 | 2006-11-21 | The Regents Of The University Of California | Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| US6482795B1 (en) | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
| WO1998033912A1 (en) | 1997-01-30 | 1998-08-06 | Human Genome Sciences, Inc. | MYELIN OLIGODENDROCYTE GLYCOPROTEIN-LIKE PROTEIN (MOGp) AND METHODS OF USE |
| US20030192065A1 (en) | 1998-02-06 | 2003-10-09 | Matthew D. Linnik | Human nerve growth factor exon 1 and exon 3 promoters |
| DE19704301C1 (de) | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| WO1998037194A1 (en) | 1997-02-19 | 1998-08-27 | Human Genome Sciences, Inc. | Ell2, a member of an ell family of rna polymerase ii elongation factors |
| US5965790A (en) | 1997-03-06 | 1999-10-12 | Millennium Pharmaceuticals, Inc. | SR-BI regulatory sequences and therapeutic methods of use |
| US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
| US20020142417A1 (en) | 1997-04-02 | 2002-10-03 | Beverly Paigen | Antioxidant protein 2, gene and methods of use therefor |
| US6410312B1 (en) | 1997-12-19 | 2002-06-25 | Chiron Corporation | huBUB3 gene involved in human cancers |
| US6548736B1 (en) * | 1997-06-13 | 2003-04-15 | President And Fellows Of Harvard College | 7B2 knockout transgenic animals as models of endocrine disease |
| EP0893493A3 (de) * | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
| US6287558B1 (en) | 1997-08-01 | 2001-09-11 | Biohybrio Technologies Llc | Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule |
| US6040168A (en) | 1997-08-06 | 2000-03-21 | The Rockefeller University | DNA encoding the human synapsin III gene and uses thereof |
| US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| US6015709A (en) * | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US20020048792A1 (en) | 1997-08-26 | 2002-04-25 | Ariad Gene Therapeutics, Inc. | Methods and materials for regulated production of proteins |
| US6255473B1 (en) | 1997-08-29 | 2001-07-03 | Duke University | Presenilin-1 gene promoter |
| US20040103448A1 (en) * | 1997-09-05 | 2004-05-27 | Anders Bjorklund | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| EP1025223A2 (en) | 1997-09-19 | 2000-08-09 | Magainin Pharmaceuticals Inc. | Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| US6087164A (en) | 1997-10-03 | 2000-07-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| AU1085099A (en) | 1997-10-16 | 1999-05-03 | Children's Medical Center Corporation | Thymosin beta15 promoter and use thereof |
| US6383746B1 (en) | 1997-10-23 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Functional promoter for CCR5 |
| US20020111325A1 (en) | 1997-11-03 | 2002-08-15 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
| WO1999023216A2 (en) * | 1997-11-03 | 1999-05-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US6509190B2 (en) * | 1997-11-12 | 2003-01-21 | The Trustees Of Columbia University In The City Of New York | DNA regulatory element for the expression of transgenes in neurons of the mouse forebrain |
| US7063960B2 (en) | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
| US6368612B1 (en) | 1997-12-12 | 2002-04-09 | Biohybrid Technologies Llc | Devices for cloaking transplanted cells |
| US6930175B1 (en) | 1997-12-12 | 2005-08-16 | The Johns Hopkins University School Of Medicine | Gene family with transformation modulating activity |
| US6335156B1 (en) | 1997-12-18 | 2002-01-01 | The Johns Hopkins University School Of Medicine | 14-3-3σ arrests the cell cycle |
| US6432668B1 (en) | 1997-12-30 | 2002-08-13 | Chiron Corporation | Polynucleotides encoding human cyclin-dependent kinase (hPFTAIRE) |
| US6015376A (en) * | 1998-01-13 | 2000-01-18 | University Of Kentucky Research Foundation | DNA sequence corresponding to the minimal essential promoter of the human sodium-iodide symporter (hNIS) |
| US6780610B1 (en) | 1998-01-16 | 2004-08-24 | Setagon, Inc. | Identification of a smooth muscle cell (SMC) specific smooth muscle heavy chain (SM-MHC) promoter/enhancer |
| GB9801902D0 (en) | 1998-01-29 | 1998-03-25 | Cancer Res Campaign Tech | A gene promoter |
| TR200002496T2 (tr) * | 1998-02-27 | 2000-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi. |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6207812B1 (en) | 1998-03-13 | 2001-03-27 | Rhode Island Hospital | Chondrosarcoma associated genes |
| US6866842B1 (en) * | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
| US6342596B1 (en) * | 1998-05-05 | 2002-01-29 | Hsf Pharmaceuticals S.A. | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US7279565B2 (en) | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| DK1075262T3 (da) * | 1998-05-05 | 2005-11-14 | Sepracor Inc | Desmethylpantoprazolpræparater og -fremgangsmåder |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US20020023277A1 (en) * | 1998-05-22 | 2002-02-21 | Heidi Stuhlmann | Vascular endothelial zinc finger 1 gene and protein and uses thereof |
| EP1078059A2 (en) | 1998-06-12 | 2001-02-28 | Chiron Corporation | Cif130 inhibits cell cycle progression |
| US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US6262249B1 (en) | 1998-06-23 | 2001-07-17 | Chiron Corporation | Pancreatic cancer genes |
| US6610509B1 (en) | 1998-07-24 | 2003-08-26 | Barnes-Jewish Hospital | Methods of targeted expression by the CD-RAP gene promoter |
| AU5243299A (en) | 1998-07-29 | 2000-02-21 | Tularik Inc. | Uncoupling protein-2(hcp2): compositions and methods of use |
| US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
| JP4768916B2 (ja) | 1998-09-15 | 2011-09-07 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入 |
| CA2245903A1 (en) | 1998-09-28 | 2000-03-28 | Mcgill University | Use of pex in the treatment of metabolic bone diseases |
| US6387656B1 (en) | 1998-09-29 | 2002-05-14 | The Trustees Of Columbia University In The City Of New York | Gene encoding MNR2 and uses thereof |
| DE19849044A1 (de) * | 1998-10-23 | 2000-04-27 | Univ Ludwigs Albert | Das Gen PRV-1 und dessen Verwendung |
| AU2352700A (en) * | 1998-12-04 | 2000-06-19 | G.D. Searle & Co. | Nucleic acids, polypeptides, vectors, and cells derived from activated eosinophil cells |
| US6174679B1 (en) * | 1998-12-10 | 2001-01-16 | Chiron Corporation | CIF150/hTAFII150 is necessary for cell cycle progression |
| AU1805300A (en) | 1998-12-12 | 2000-07-03 | Jae Ho Lee | Cancer diagnosis method using cell growth inhibiting and cell differentiation specific syg972 gene and genomic dna and promoter thereof |
| ATE408695T1 (de) | 1998-12-16 | 2008-10-15 | Novartis Vaccines & Diagnostic | Menschliche cyclin-abhängige kinase (hpnqalre) |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
| US6395482B1 (en) | 1999-01-13 | 2002-05-28 | The Rockfeller University | Method of determining susceptibility to schizophrenia |
| US7148016B1 (en) | 1999-01-14 | 2006-12-12 | Ca*Tx Inc. | Immunoassays to detect diseases or disease susceptibility traits |
| US7094533B1 (en) | 1999-01-21 | 2006-08-22 | Board Of Regents Of The University Of Nebraska | Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer |
| CN1343255A (zh) | 1999-01-25 | 2002-04-03 | 宫田敏男 | Megsin启动子 |
| EP1150994A4 (en) | 1999-02-02 | 2003-01-29 | Univ Columbia | GENES HAVING IMPROVED EXPRESSION DURING CELL SENESCENCE AND TERMINAL CELL DIFFERENTIATION, AND USES THEREOF |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6495161B1 (en) | 1999-03-09 | 2002-12-17 | Vivorx, Inc. | Cytoprotective biocompatible containment systems for biologically active materials and methods of making same |
| EP1048736A1 (en) | 1999-04-27 | 2000-11-02 | Aventis Behring Gesellschaft mit beschränkter Haftung | DNA-construct for the tissue specific expression of a blood coagulation factor |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
| AU2248500A (en) | 1999-03-31 | 2000-10-05 | Aquatic Mechanical Services Pty Ltd | Alloy water treatment |
| US7227013B1 (en) | 1999-03-31 | 2007-06-05 | Metamorphix, Inc. | Growth differentiation factor-9 regulatory sequences and uses therefor |
| US6897062B1 (en) * | 1999-04-09 | 2005-05-24 | Sloan-Kettering Institute For Cancer Research | DNA encoding the prostate-specific membrane antigen-like gene and uses thereof |
| EP1180114B1 (en) | 1999-04-27 | 2011-09-21 | The Trustees of The University of Pennsylvania | Use of resisitin specific antibodies in the treatment of diabetes |
| US6277970B1 (en) | 1999-05-11 | 2001-08-21 | The Regents Of The University Of California | PRP-like gene |
| US6558665B1 (en) | 1999-05-18 | 2003-05-06 | Arch Development Corporation | Encapsulating particles with coatings that conform to size and shape of the particles |
| US6541244B1 (en) | 1999-06-07 | 2003-04-01 | Cedars-Sinai Medical Center | Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans |
| US6284882B1 (en) | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
| AU5689800A (en) | 1999-06-15 | 2001-01-02 | Imperial Cancer Research Technology Limited | Diagnosis, prognosis and treatment of cancer related to the barx2 gene |
| US7049132B1 (en) | 1999-06-28 | 2006-05-23 | University Of Southern California | Stress-responsive induction of a therapeutic agent and methods of use |
| WO2001000818A1 (fr) | 1999-06-29 | 2001-01-04 | Nippon Kayaku Kabushiki Kaisha | Gene codant le domaine promoteur du gene suppresseur de tumeur p51 et utilisation |
| WO2001000825A2 (en) | 1999-06-30 | 2001-01-04 | Chiron Corporation | Human chromosome 15 and 16 bardet-biedl syndrome polynucleotides and polypeptides and methods of use |
| US7276595B2 (en) | 1999-07-14 | 2007-10-02 | Hong Kong University Of Science & Technology Inc. | DNA sequence encoding a retinoic acid regulated protein |
| US6320038B1 (en) | 1999-08-03 | 2001-11-20 | Pertti Aarre Juhani Panula | Promoter for neuropeptide FF and use thereof for therapy and diagnostics |
| US6416956B1 (en) * | 1999-08-13 | 2002-07-09 | George Washington University | Transcription factor, BP1 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2383358A1 (en) | 1999-08-31 | 2001-03-08 | Board Of Regents, The University Of Texas System | Methods and compositions of a novel serine protease inhibitor |
| EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
| US20020042062A1 (en) | 1999-09-24 | 2002-04-11 | Mark Stearns | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
| US7790861B2 (en) | 1999-09-24 | 2010-09-07 | Philadelphia Health And Education Corporation | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
| DE19947668A1 (de) | 1999-10-04 | 2001-04-19 | Univ Eberhard Karls | Tumorspezifischer Vektor für die Gentherapie |
| DE19949179A1 (de) * | 1999-10-12 | 2001-05-03 | Univ Bremen | Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse |
| AU7921200A (en) * | 1999-10-20 | 2001-04-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | A new EAG gene |
| US6716824B1 (en) | 1999-10-22 | 2004-04-06 | F. Charles Brunicardi | Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy |
| US20040091928A1 (en) | 1999-10-27 | 2004-05-13 | Pharmacia & Upjohn Company | G protein-coupled receptors expressed in brain |
| US20030078224A1 (en) | 1999-10-29 | 2003-04-24 | Chung Leland W.K. | Gene expression directed by a super-PSA promoter |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US6881834B1 (en) | 2000-01-03 | 2005-04-19 | Guthrie Foundation For Education And Research | Myeloid cell promoter and constructs containing same |
| US6569684B2 (en) * | 2000-01-06 | 2003-05-27 | University Of Central Florida | Method of identifying and treating invasive carcinomas |
| US6743903B1 (en) | 2000-01-18 | 2004-06-01 | The Regents Of The University Of California | Nucleic acids for the diagnosis and treatment of giant cell arteritis |
| US20020119452A1 (en) | 2000-01-18 | 2002-08-29 | Phippard Deborah J. | Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells |
| US20020042057A1 (en) * | 2000-02-03 | 2002-04-11 | Ralph Knoell | MLP-gene, nucleic acids, polypeptides and use thereof |
| ES2330918T3 (es) | 2000-02-11 | 2009-12-17 | Genentech, Inc. | Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion. |
| DE10008330A1 (de) * | 2000-02-23 | 2001-09-06 | Switch Biotech Ag | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren der Genfamilie NM23 zur Diagnose oder Behandlung von Haut- und Darmerkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen. |
| ES2336817T3 (es) | 2000-02-25 | 2010-04-16 | Siemens Healthcare Diagnostics Inc. | Marcadores relacionados con la endometriosis y usos de los mismos. |
| KR20030072205A (ko) | 2000-02-28 | 2003-09-13 | 디코드 제네틱스 이에이치에프 | 사람 정신분열증 유전자 |
| CA2400595A1 (en) | 2000-02-28 | 2001-09-07 | Decode Genetics Ehf | Human schizophrenia gene |
| US6841362B1 (en) * | 2000-02-29 | 2005-01-11 | The Trustees Of Columbia University In The City Of New York | Melanoma differentiation associated gene-7 promoter and uses thereof |
| MXPA02008487A (es) | 2000-02-29 | 2002-12-13 | Alcon Lab Inc | Diagnosticos y terapeutica del glaucoma. |
| AU4347701A (en) | 2000-03-01 | 2001-09-12 | Corixa Corp | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| JP2004500097A (ja) | 2000-03-02 | 2004-01-08 | エムエル ラボラトリーズ ピーエルシー | Ｔｃｆ応答性エレメント |
| FR2806418B1 (fr) * | 2000-03-14 | 2004-07-16 | Aventis Pharma Sa | Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations |
| US20030157072A1 (en) | 2000-03-16 | 2003-08-21 | Roger Bouillon | Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| ATE338135T1 (de) | 2000-03-22 | 2006-09-15 | Rheogene Holdings Inc | Induziertes genexpressionssystem basierend auf ecdysonrezeptoren |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| NZ522282A (en) | 2000-04-04 | 2005-03-24 | Univ Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| WO2001079290A2 (en) | 2000-04-13 | 2001-10-25 | 1149336 Ontario Inc. | Glp-2 receptor gene promoter and uses thereof |
| EP1914554B1 (en) * | 2000-04-20 | 2010-06-09 | St Vincent's Hospital Sydney Limited | Diagnostic assay involving macrophage inhibitory cytokine-1 (MIC-1) |
| US20020009455A1 (en) * | 2000-04-27 | 2002-01-24 | Ted Lau | DNA encoding a novel PROST 03 polypeptide |
| US7071323B2 (en) | 2000-05-02 | 2006-07-04 | Wisconsin Alumni Research Foundation | Promoter sequences for corticotropin releasing-factor receptor CRF2α and method of identifying agents that alter the activity of the promoter sequences |
| DE10024171A1 (de) | 2000-05-17 | 2001-12-20 | Basf Lynx Bioscience Ag | Neuronale Serin-Threonin-Protein-Kinase |
| CA2810249A1 (en) | 2000-06-05 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| AU2001268232A1 (en) | 2000-06-09 | 2001-12-24 | The Trustees Of The University Of Pennsylvania | Compositions, methods, and kits relating to resistin-like molecules |
| US6337008B1 (en) | 2000-06-12 | 2002-01-08 | Alcan International Limited | Electrolysis cells |
| WO2001098530A2 (en) * | 2000-06-19 | 2001-12-27 | Vereniging Het Nederlands Kanker Instituut | Interaction of tbx2 and the arf promoter in cell cycle regulator assays |
| US20030180302A1 (en) | 2000-06-20 | 2003-09-25 | Eckhard Wolf | Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances |
| GB0015371D0 (en) | 2000-06-23 | 2000-08-16 | Novartis Res Found | Tumour-cell specific gene expression and its use in cancer therapy |
| US6723553B2 (en) | 2000-06-27 | 2004-04-20 | Biovitrum Ab | Promoter sequences |
| FR2811678B1 (fr) | 2000-07-12 | 2002-09-27 | Inst Nat Sante Rech Med | Promoteur specifique du myocarde |
| EP1762614A3 (en) | 2000-07-21 | 2007-05-30 | Research Corporation Technologies, Inc. | Tumor-specific promoters |
| CA2417134A1 (en) | 2000-07-25 | 2002-01-31 | The Sir Mortimer B. Davis - Jewish General Hospital | Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| US20050181374A1 (en) | 2004-01-05 | 2005-08-18 | Mount Sinai School Of Medicine Of New York University | Kruppel-like factor 6 ( KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein |
| WO2002012285A2 (en) | 2000-08-10 | 2002-02-14 | Board Of Regents, The University Of Texas System | The tumor suppressor car-1 |
| US7195910B2 (en) * | 2000-08-30 | 2007-03-27 | Thomas Jefferson University | Human tyrosine hydroxylase promoter and uses thereof |
| AUPQ980600A0 (en) | 2000-09-01 | 2000-09-21 | Bionomics Limited | Tumour suppressor gene |
| US20040014706A1 (en) * | 2000-09-11 | 2004-01-22 | Franz-Werner Kluxen | Use of carp inhibitors for the treatment of heart diseases |
| US6630304B1 (en) | 2000-09-14 | 2003-10-07 | Decode Genetics Ehf. | Human osteoporosis gene |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| US20030017573A1 (en) * | 2000-10-04 | 2003-01-23 | Board Of Regents, The University Of Texas System | Polymerase kappa compositions and methods thereof |
| ATE360063T1 (de) | 2000-10-12 | 2007-05-15 | Agency Science Tech & Res | Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen |
| US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| JP2004517634A (ja) | 2000-10-27 | 2004-06-17 | ベイラー カレッジ オブ メディシン | 神経変性疾患の同定と治療のための方法及び組成物 |
| WO2002036624A2 (en) | 2000-10-30 | 2002-05-10 | Board Of Regents, The University Of Texas System | Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof |
| US20020151018A1 (en) | 2000-10-31 | 2002-10-17 | Prouty Stephen M. | Stearoyl-CoA desaturase gene promoter |
| US6670138B2 (en) | 2000-11-01 | 2003-12-30 | Agy Therapeutics, Inc. | Method of diagnosing ischemic stroke via UCP-2 detection |
| EP1205490A1 (en) | 2000-11-10 | 2002-05-15 | ARTEMIS Pharmaceuticals GmbH | Fusion protein comprising integrase (phiC31) and a signal peptide (NLS) |
| US20040003420A1 (en) | 2000-11-10 | 2004-01-01 | Ralf Kuhn | Modified recombinase |
| AU2002225714A1 (en) | 2000-11-10 | 2002-05-21 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| DE60127291T2 (de) * | 2000-11-20 | 2007-12-20 | California Institute Of Technology, Pasadena | Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung |
| WO2002044331A2 (en) | 2000-11-29 | 2002-06-06 | Cangen International | Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer |
| WO2003051402A1 (en) | 2000-12-05 | 2003-06-26 | Uab Research Foundation | Adenoviral vector containing cyclooxygenase-2 promoter and uses thereof |
| CN1483040A (zh) * | 2000-12-07 | 2004-03-17 | ��������I�����ɷ� | 心锚蛋白重复蛋白基因上游序列、含有该序列的载体及其用途 |
| US7220844B2 (en) | 2000-12-14 | 2007-05-22 | Wisconsin Alumni Research Foundation | Liver tumor marker sequences |
| CA2431478A1 (en) | 2000-12-22 | 2002-07-04 | Locomogene, Inc. | Synovial cell protein |
| US7247705B2 (en) | 2000-12-28 | 2007-07-24 | Takeda Pharmaceutical Company Limited | Proteins having glucose transporter activity |
| WO2002054940A2 (en) | 2001-01-12 | 2002-07-18 | University Of Medicine & Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| KR100418465B1 (ko) | 2001-01-15 | 2004-02-14 | 서동상 | 인슐린 의존성 당뇨병의 유전자 치료방법 및 그 치료용 조성물 |
| US20030013097A1 (en) | 2001-01-23 | 2003-01-16 | Welsh John Barnard | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| US7413873B2 (en) | 2001-01-30 | 2008-08-19 | The Regents Of The University Of California | Method of detection and treatment of colon cancer |
| US20020169300A1 (en) | 2001-01-30 | 2002-11-14 | Waterman Marian L. | Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 |
| EP1409536A2 (en) * | 2001-02-12 | 2004-04-21 | Curagen Corporation | Human proteins and nucleic acids encoding same |
| PT1456346E (pt) | 2001-02-20 | 2012-05-02 | Intrexon Corp | Novo sistema de expressão de genes induzido baseado no recetor de ecdisona / recetor x retinoide invertebrado |
| EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| CA2445796C (en) | 2001-02-20 | 2014-09-16 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| EP1572862B1 (en) | 2001-02-20 | 2012-08-01 | Intrexon Corporation | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
| WO2002078729A1 (en) | 2001-03-29 | 2002-10-10 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
| US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
| CA2443968A1 (en) | 2001-04-12 | 2002-10-24 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: i |
| US7078411B2 (en) | 2001-05-16 | 2006-07-18 | Umdnj (Univ Of Medicine & Dentist. Of Nj) | Phospholipid transfer protein (PLTP) and cholestoral metabolism |
| WO2002094084A2 (en) | 2001-05-21 | 2002-11-28 | University Of Iowa Research Foundation | Bmpr1a involvement in juvenile polyposis |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| KR20030022094A (ko) | 2001-05-24 | 2003-03-15 | (주)휴먼디엔에이테크놀로지 | 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체 |
| US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| DE10126473A1 (de) * | 2001-05-31 | 2003-09-04 | Daniel Peter | Methode zur Diagnose und Therapie des Nierenzellkarzinoms |
| WO2002098432A1 (en) * | 2001-06-01 | 2002-12-12 | The Brigham And Women's Hospital, Inc. | Methods of treating cardiac disorders |
| US20040259777A1 (en) | 2001-06-07 | 2004-12-23 | Kenneth Thirstrup | Method of treating metabolic disorders using neuronatin polypeptides |
| WO2002100876A1 (en) * | 2001-06-11 | 2002-12-19 | The General Hospital Corporation | Dock 3 tumor suppressor gene |
| AU2002345659A1 (en) | 2001-06-13 | 2002-12-23 | The Johns Hopkins University School Of Medicine | Cloned mammalian polyamine oxidase |
| US20040086504A1 (en) | 2001-06-21 | 2004-05-06 | Deepak Sampath | Cyr61 as a target for treatment and diagnosis of breast cancer |
| EP1409734A4 (en) * | 2001-06-27 | 2005-10-19 | New England Medical Center Inc | DIAGNOSIS AND TREATMENT OF CANCER |
| US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| US20050079496A1 (en) | 2001-08-17 | 2005-04-14 | Edgar Serfling | Methods for diagnosing and treating neoplasias using nf-at transcriptions factors |
| KR100453853B1 (ko) | 2001-08-28 | 2004-10-20 | 삼성전자주식회사 | 저전압 불 휘발성 반도체 메모리 장치 및 그것의 독출 방법 |
| CA2357181A1 (en) | 2001-08-31 | 2003-02-28 | Procyon Biopharma Inc. | Generation of transgenic mouse models for the development of prostate cancer using regulatory regions of the psp94 gene |
| US20030096781A1 (en) | 2001-08-31 | 2003-05-22 | University Of Southern California | IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma |
| US20030108920A1 (en) | 2001-09-07 | 2003-06-12 | Wei Zhang | Tumor suppressor-like proteins that bind IGFBP2 |
| US7247297B2 (en) | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
| WO2003025190A1 (fr) * | 2001-09-14 | 2003-03-27 | The New Industry Research Organization | Agent promoteur de tumeur specifique et utilisation associee |
| US7202024B2 (en) | 2001-09-17 | 2007-04-10 | Immunogen Inc. | bbc3 Gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoter |
| AU2002327945A1 (en) | 2001-09-17 | 2003-04-01 | Eirx Therapeutics Limited | Human delta-n p73 molecules and uses thereof |
| CA2820170C (en) | 2001-09-26 | 2016-07-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| CA2459827C (en) | 2001-09-26 | 2013-09-03 | Subba Reddy Palli | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| AU2002347779A1 (en) | 2001-10-01 | 2003-04-14 | The General Hospital Corporation | Diagnosing, treating, and preventing cancer using cables |
| GB0123664D0 (en) | 2001-10-02 | 2001-11-21 | Inst Of Cancer Res The | Histone deacetylase 9 |
| AU2002335093A1 (en) | 2001-10-19 | 2003-04-28 | Riken | Nr3b nmda receptor subunit compositions and related methods |
| US7781413B2 (en) | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
| JP2005508171A (ja) | 2001-11-02 | 2005-03-31 | タノックス インコーポレーテッド | Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原 |
| US20050107315A1 (en) | 2001-11-21 | 2005-05-19 | Board Of Regents Of The University Of Nebraska | Mammary-associated serum amuloid a3 promoter sequences and used for same |
| AU2002351214B2 (en) | 2001-12-03 | 2008-09-11 | Metabolex, Inc. | Methods and reagents for diagnosis and treatment of diabetes |
| US20060275747A1 (en) | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
| AU2002364722A1 (en) | 2001-12-07 | 2003-06-23 | Wella Ag | Methods and compositions for diagnosing and treating hypotrichosis simplex |
| US7166713B2 (en) * | 2001-12-11 | 2007-01-23 | Texas Techn University | Variant cleavage stimulation factor and its encoding nucleic acid |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| US7432349B2 (en) | 2002-01-23 | 2008-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor suppressor gene, p28ING5 |
| US20030203380A1 (en) | 2002-01-25 | 2003-10-30 | Decode Genetics Ehf. | Gene linked to osteoarthritis |
| US7053193B2 (en) | 2002-01-25 | 2006-05-30 | Origene Technologies, Inc. | Breast cancer transcription factor gene and uses |
| US20030180728A1 (en) | 2002-03-22 | 2003-09-25 | Kovacs Karl F. | Human BCU399 gene, polypeptide, and uses |
| US20030157599A1 (en) | 2002-01-30 | 2003-08-21 | Decode Genetics Ehf | Gene for peripheral arterial occlusive disease |
| AU2003219696A1 (en) | 2002-02-01 | 2003-09-02 | Seattle Genetics, Inc. | Sga-1m, a cancer associated antigen, and uses thereof |
| GB0219574D0 (en) | 2002-02-14 | 2002-10-02 | Aventis Pharma Inc | A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| AU2003213051A1 (en) * | 2002-02-14 | 2003-09-04 | Aventis Pharmaceuticals, Inc. | A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| US20040005294A1 (en) * | 2002-02-25 | 2004-01-08 | Ho-Young Lee | IGFBP-3 in the diagnosis and treatment of cancer |
| EP1340818A1 (en) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| ATE364096T1 (de) | 2002-03-20 | 2007-06-15 | Novartis Pharma Gmbh | Verfahren zur diagnose und therapie von schizophrenie |
| WO2003083049A2 (en) | 2002-03-22 | 2003-10-09 | Munin Corporation | Cloning and characterization of g+c-rich promoter binding protein |
| US6727322B2 (en) | 2002-04-01 | 2004-04-27 | The University Of Akron | Amphiphilic networks, implantable immunoisolatory devices, and methods of preparation |
| EP1578926A4 (en) | 2002-04-19 | 2006-11-02 | Schering Ag | NEW PROMOTER SPECIFIC TO PROSTATIC TUMOR |
| AU2003221579A1 (en) * | 2002-04-30 | 2003-11-17 | Canadian Blood Services | Encapsulated cells to elicit immune response |
| EP1560842A4 (en) | 2002-05-03 | 2006-04-19 | Univ Texas | MTA1S, A STEROID HORMONE RECEPTOR COREPRESSOR |
| US20060052320A1 (en) * | 2002-05-06 | 2006-03-09 | Limin Li | Mammalian genes involved in rapamycin resistance and tumorgenesis annexin XIII genes |
| WO2003095972A2 (en) * | 2002-05-09 | 2003-11-20 | The Regents Of The University Of California | Method of analyzing ataxia-telangiectasia protein |
| US7087385B2 (en) | 2002-05-16 | 2006-08-08 | Wisconsin Alumni Research Foundation | Promoter sequences for urocortin II and the use thereof |
| US20040029158A1 (en) * | 2002-05-17 | 2004-02-12 | Eric Olson | HOP - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification |
| US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
| JP2005535302A (ja) | 2002-06-04 | 2005-11-24 | メタボレックス インコーポレーティッド | 糖尿病およびインスリン抵抗性の診断および治療のための方法 |
| WO2003101284A2 (en) | 2002-06-04 | 2003-12-11 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
| EP1511850A4 (en) | 2002-06-10 | 2006-06-07 | Metabolex Inc | METHODS OF TREATING AND DIAGNOSING DIABETES USING MODULATORS OF CX3CR1 |
| US20060210974A1 (en) | 2002-06-13 | 2006-09-21 | Metabolex, Inc. | Compositions and methods for preventing, treating and diagnosing diabetes |
| US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2004001047A1 (ja) * | 2002-06-20 | 2003-12-31 | Yamanouchi Pharmaceutical Co., Ltd. | 新規プロモーター |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| GB0216286D0 (en) * | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
| US7129328B2 (en) | 2002-07-17 | 2006-10-31 | Wisconsin Alumni Research Foundation | Liver tumor marker sequences |
| US7364727B2 (en) | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
| KR100493887B1 (ko) | 2002-08-09 | 2005-06-08 | 한국과학기술연구원 | 내환경성 클래드 판재 및 그 제조방법 |
| AU2003265525A1 (en) | 2002-08-15 | 2004-03-19 | Functional Genetics, Inc. | Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes |
| US20060099676A1 (en) | 2002-08-15 | 2006-05-11 | Limin Li | Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes |
| US20040126824A1 (en) | 2002-08-20 | 2004-07-01 | Liu Hsi-Chou Cedric | Ovarian cancer-specific promoter |
| AU2002951346A0 (en) * | 2002-09-05 | 2002-09-26 | Garvan Institute Of Medical Research | Diagnosis of ovarian cancer |
| US20040049437A1 (en) * | 2002-09-11 | 2004-03-11 | Govone Solutions, Lp | Method, system and computer program product for automating transaction tax calculation |
| AU2003278918A1 (en) | 2002-09-23 | 2004-04-08 | The General Hospital Coporation | Methods for diagnosing and treating tumors and suppressing cd promoters |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| IL152232A0 (en) | 2002-10-10 | 2003-05-29 | Yeda Res & Dev | Promoter to il-18bp, its preparation and use |
| US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
| WO2004035535A2 (en) | 2002-10-15 | 2004-04-29 | Yeda Research And Development Co. Ltd. | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
| US20040076965A1 (en) | 2002-10-16 | 2004-04-22 | Bosserhoff Anja Katrin | MIA-2 protein |
| BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
| CA2501514A1 (en) | 2002-11-01 | 2004-05-21 | Decode Genetics Ehf. | Human type ii diabetes gene-slit-3 located on chromosome 5q35 |
| US20050196784A1 (en) | 2002-11-01 | 2005-09-08 | Decode Genetics Ehf. | Human Type II diabetes gene - Kv channel-interacting protein (KChIP1) located on chromosome 5 |
| CN102304570B (zh) | 2002-11-13 | 2015-01-21 | 托马斯杰斐逊大学 | 用于癌症诊断和治疗的组合物和方法 |
| WO2004044170A2 (en) | 2002-11-13 | 2004-05-27 | Metabolex, Inc. | A pancreatic islet transcription factor and uses thereof |
| US20040197770A1 (en) | 2002-11-14 | 2004-10-07 | Mount Sinai School Of Medicine | Induction of apoptosis by HIV-1 infected monocytic cells |
| GB0228337D0 (en) | 2002-12-05 | 2003-01-08 | Yorkshire Cancer Res Campaign | Replication protein |
| CA2507811C (en) * | 2002-12-09 | 2013-11-05 | Antonio Camargo | Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) [af217798] |
| AU2002953341A0 (en) | 2002-12-13 | 2003-01-09 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
| AU2003303347A1 (en) | 2002-12-21 | 2004-07-22 | Universitat Leipzig | Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs |
| EP1592454A1 (en) * | 2003-01-22 | 2005-11-09 | Magnus Essand | Tarp promoter and uses thereof |
| WO2004069194A2 (en) * | 2003-02-03 | 2004-08-19 | The Brigham And Women's Hospital, Inc. | Use of the oxidoreductase ncb50r for diagnosings and treating diabetes |
| US20040171108A1 (en) | 2003-02-07 | 2004-09-02 | Fisher Paul B. | Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| NZ603330A (en) | 2003-02-11 | 2015-02-27 | Shire Human Genetic Therapies | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
| US7745689B2 (en) | 2003-02-14 | 2010-06-29 | Akari Inada | Nephropathy-associated gene |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| KR100523028B1 (ko) * | 2003-02-27 | 2005-10-20 | 윤채옥 | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 |
| EP1639108A2 (en) * | 2003-02-28 | 2006-03-29 | McGILL UNIVERSITY | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20070166711A1 (en) | 2003-04-15 | 2007-07-19 | Samuels Mark E | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
| US20050054826A1 (en) * | 2003-05-19 | 2005-03-10 | Rosetta Inpharmatics Llc | Human diaphanous-3 gene and methods of use therefor |
| US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| WO2004109288A1 (en) | 2003-06-06 | 2004-12-16 | Astrazeneca Ab | Method for diagnosing inflammatory bowel disease |
| WO2005002413A2 (en) | 2003-07-01 | 2005-01-13 | Bar Ilan University | Methods and reagents for diagnosing gliomas and treating gliomas |
| WO2005020888A2 (en) | 2003-07-02 | 2005-03-10 | Saint Louis University | Compositions and methods of treating and diagnosing hepatoma |
| US7056927B2 (en) | 2003-07-07 | 2006-06-06 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US7556942B2 (en) * | 2003-07-15 | 2009-07-07 | Board Of Regents, The University Of Texas System | Tumor suppressor designated Hippo |
| BRPI0413197A (pt) | 2003-08-01 | 2006-10-03 | Amgen Inc | cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept |
| EP1651161B1 (en) * | 2003-08-07 | 2011-10-19 | HealOr Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| WO2005017164A1 (en) * | 2003-08-11 | 2005-02-24 | University Of South Florida | Vigilant cells |
| WO2005018431A2 (en) * | 2003-08-19 | 2005-03-03 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating neurological conditions |
| WO2005033297A1 (en) * | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
| SE526959C2 (sv) | 2003-10-02 | 2005-11-29 | Tikomed Ab | Bioartificellt implantat innefattande en semipermeabel barriär samt förfarande för reducering av risken för bildning av bindrväv vid implantatet efter implantering genom att barriären förses med en permeabel beläggning av bioaktiv metall |
| US20050123538A1 (en) | 2003-10-03 | 2005-06-09 | Ronen Shemesh | Polynucleotides encoding novel ErbB-2 polypeptides and kits and methods using same |
| US7482156B2 (en) | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
| US20070028314A1 (en) * | 2003-10-20 | 2007-02-01 | Toshihisa Komori | Bone and/or joint disease-associated genes |
| EP1680447A2 (en) | 2003-10-24 | 2006-07-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Orthogonal gene switches |
| FR2863275B1 (fr) | 2003-12-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnostic/pronostic du cancer du sein |
| TWI398261B (zh) | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
| US20050153352A1 (en) | 2004-01-09 | 2005-07-14 | Stanley Chang | Cancer specific gene MG20 |
| FR2866349B1 (fr) | 2004-02-12 | 2008-05-16 | Biomerieux Sa | Procede de diagnostic/pronostic d'une thrombose |
| US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| WO2005084109A2 (en) * | 2004-03-08 | 2005-09-15 | Medigen Biotechnology Corporation | Cancer specific gene mh15 |
| US7582442B2 (en) * | 2004-03-16 | 2009-09-01 | The Regents Of The University Of Michigan | Methods and compositions for using aleveolar macrophage phospholipase A2 |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20060079675A1 (en) | 2004-05-06 | 2006-04-13 | Chen Youhai H | Compositions and use of inflammation-20 (Inf-20) gene |
| EP2484772B1 (en) | 2004-05-18 | 2016-08-17 | Intrexon Corporation | Methods for dynamic vector assembly of DNA cloning vector plasmids |
| US7704714B2 (en) * | 2004-07-26 | 2010-04-27 | Agency For Science, Technology & Research | Encapsulation of cells in biologic compatible scaffolds by coacervation of charged polymers |
| US20060070134A1 (en) * | 2004-08-12 | 2006-03-30 | Tin Tin Su | Diagnosis and treatment of fanconi's anemia |
| US7332294B2 (en) * | 2004-08-17 | 2008-02-19 | University Health Network | CXCL10-based diagnosis and treatment of respiratory illnesses |
| US20060067942A1 (en) * | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| US7629325B2 (en) | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| WO2006047233A2 (en) | 2004-10-22 | 2006-05-04 | Neurologix, Inc. | Pink-1 promoter |
| MX2007007409A (es) | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
| ES2380779T3 (es) | 2004-12-20 | 2012-05-18 | Wyeth Llc | Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| US20060194235A1 (en) | 2005-02-25 | 2006-08-31 | Jian-Wei Chen | HLJ1 gene expression |
| US7868159B2 (en) * | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20070037194A1 (en) * | 2005-08-09 | 2007-02-15 | Vanderbilt University | Allelic variation in the serotonin transporter (SERT) as an indicator of autism |
| US20070036770A1 (en) * | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
| US7576191B2 (en) * | 2005-09-13 | 2009-08-18 | Vanderbilt University | Tumor suppressor Killin |
| US9265814B2 (en) * | 2005-12-30 | 2016-02-23 | Neurotech Usa, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| EP3357904B1 (en) | 2007-05-29 | 2022-07-06 | Precigen, Inc. | Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| AU2008289461A1 (en) * | 2007-08-23 | 2009-02-26 | Intrexon Corporation | Methods and compositions for diagnosing disease |
| EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| ES2531522T3 (es) | 2007-10-08 | 2015-03-16 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
| WO2010042189A2 (en) | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
| ITUA20162720A1 (it) | 2016-04-19 | 2017-10-19 | Risco Spa | Apparecchiatura per preparare un prodotto alimentare |
-
2008
- 2008-09-29 EP EP08834828.9A patent/EP2205249B1/en not_active Not-in-force
- 2008-09-29 CN CN200880117657A patent/CN101868241A/zh active Pending
- 2008-09-29 MX MX2010003371A patent/MX2010003371A/es active IP Right Grant
- 2008-09-29 US US12/241,018 patent/US20090136465A1/en not_active Abandoned
- 2008-09-29 WO PCT/US2008/011270 patent/WO2009045370A2/en active Application Filing
- 2008-09-29 NZ NZ584848A patent/NZ584848A/xx not_active IP Right Cessation
- 2008-09-29 JP JP2010526971A patent/JP2010540534A/ja active Pending
- 2008-09-29 BR BRPI0817233-1A patent/BRPI0817233A2/pt not_active IP Right Cessation
- 2008-09-29 CA CA2715080A patent/CA2715080C/en not_active Expired - Fee Related
- 2008-09-29 RU RU2010116781/15A patent/RU2499599C2/ru not_active IP Right Cessation
- 2008-09-29 AU AU2008307643A patent/AU2008307643B9/en not_active Ceased
- 2008-09-29 KR KR1020107009417A patent/KR101666228B1/ko active IP Right Grant
-
2010
- 2010-03-25 IL IL204731A patent/IL204731B/en active IP Right Grant
- 2010-04-22 ZA ZA2010/02848A patent/ZA201002848B/en unknown
-
2014
- 2014-09-25 JP JP2014194729A patent/JP2015038102A/ja active Pending
-
2015
- 2015-09-24 US US14/864,265 patent/US9724430B2/en active Active
-
2017
- 2017-06-29 US US15/637,624 patent/US10314926B2/en not_active Expired - Fee Related
-
2019
- 2019-04-22 US US16/390,434 patent/US20190343967A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009045370A2 (en) | 2009-04-09 |
| AU2008307643B9 (en) | 2014-04-17 |
| JP2015038102A (ja) | 2015-02-26 |
| CN101868241A (zh) | 2010-10-20 |
| KR20100087303A (ko) | 2010-08-04 |
| EP2205249B1 (en) | 2018-11-07 |
| US9724430B2 (en) | 2017-08-08 |
| EP2205249A4 (en) | 2010-12-22 |
| IL204731A0 (en) | 2010-11-30 |
| ZA201002848B (en) | 2011-08-31 |
| JP2010540534A (ja) | 2010-12-24 |
| KR101666228B1 (ko) | 2016-10-13 |
| US20190343967A1 (en) | 2019-11-14 |
| BRPI0817233A2 (pt) | 2012-11-06 |
| CA2715080C (en) | 2021-09-28 |
| WO2009045370A3 (en) | 2010-04-22 |
| RU2499599C2 (ru) | 2013-11-27 |
| CA2715080A1 (en) | 2009-04-09 |
| US20180126007A1 (en) | 2018-05-10 |
| US10314926B2 (en) | 2019-06-11 |
| AU2008307643B2 (en) | 2014-03-27 |
| NZ584848A (en) | 2012-09-28 |
| US20090136465A1 (en) | 2009-05-28 |
| US20160114059A1 (en) | 2016-04-28 |
| IL204731B (en) | 2018-02-28 |
| AU2008307643A1 (en) | 2009-04-09 |
| EP2205249A2 (en) | 2010-07-14 |
| MX2010003371A (es) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010116781A (ru) | Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение | |
| CA2585364C (en) | A thymus-specific protein | |
| JP5676538B2 (ja) | ポリペプチド、ポリペプチドをコードする核酸分子、及びポリペプチドを含む医薬組成物 | |
| WO2009052737A1 (fr) | Médicament destiné à la prévention et au contrôle de la maladie d'alzheimer | |
| WO2013026334A1 (zh) | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 | |
| CN107022557A (zh) | 新的死亡受体5抗体融合蛋白及其应用 | |
| JP2015502135A5 (ru) | ||
| CN105732789A (zh) | 森林山蛭镇痛肽mh2620及其基因和应用 | |
| CN113735960B (zh) | 一种fgf重组蛋白治疗nash的应用 | |
| EP1597271A2 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
| CN102127160B (zh) | 蝎活性多肽及其制备方法与应用 | |
| CN110028570A (zh) | 一种肌肉素的表达方法及其在代谢疾病中的应用 | |
| CN101117635B (zh) | Ptd、hif的odd与肿瘤抑制基因的融合表达及其应用 | |
| CN116327943A (zh) | Klf15在酒精性肝病中的应用 | |
| ES2396231T3 (es) | Complejo peptídico | |
| CN102732524B (zh) | 类HRG的七鳃鳗Lj-RGD3全RGD缺失突变体Lj-112在抗肿瘤药物中的应用 | |
| CN113307844A (zh) | 一种从猪肝中分离的具有强抗氧化性和促进脂质代谢的多肽、制备方法和应用 | |
| CN112341523A (zh) | Dleu2编码的小肽及其在制备免疫调节药物中的应用 | |
| CN104418951B (zh) | 人Nectin‑2蛋白的应用 | |
| CN101544981A (zh) | 一种具有降血糖生物活性的苦瓜多肽基因工程制备方法及应用 | |
| CN114617956B (zh) | 一种高效降糖的蛋白质药物 | |
| CN103923935A (zh) | sIL-4R-NAP融合基因 | |
| WO2010138024A2 (ru) | Средство для защиты клеток мозга | |
| Jia et al. | Programmed Cell Death 4: A New Target for Antidepressant Research | |
| CN110590926B (zh) | 一种合方鲫itln蛋白及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170930 |